乌磷布韦
化合物
乌磷布韦(英语:Uprifosbuvir,MK-3682)是一种开发用于治疗丙型肝炎的抗病毒药物。它是一种核苷酸类似物,可用作NS5B RNA聚合酶抑制剂,目前处于III期人体临床试验中。[1][2][3]
![]() | |
臨床資料 | |
---|---|
商品名 | Uprifosbuvir |
法律規範狀態 | |
法律規範 |
|
识别信息 | |
| |
CAS号 | 1496551-77-9 |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
化学信息 | |
化学式 | C22H29ClN3O9P |
摩尔质量 | 545.9 |
3D模型(JSmol) | |
| |
|
参考文献
- ^ Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Peña JM, Arias A, Barreiro P. Treatment of hepatitis C with new fixed dose combinations. Expert Opinion on Pharmacotherapy. August 2017, 18 (12): 1235–1242. PMID 28644739. doi:10.1080/14656566.2017.1346609.
- ^ Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR. NS5B polymerase inhibitors in phase II clinical trials for HCV infection. Expert Opinion on Investigational Drugs. March 2018, 27 (3): 243–250. PMID 29271672. doi:10.1080/13543784.2018.1420780.
- ^ Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, et al. Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Journal of Viral Hepatitis. September 2019, 26 (9): 1127–1138. PMID 31108015. doi:10.1111/jvh.13132.